Project Grant R01CA291708
Award Date 9/11/25
Completion Date 8/31/30
Dollars Obligated $494K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Wauwatosa, WI 53226, USA
Similar Awards
- This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $612,288 to the University of Wisconsin-Madison to conduct research on the role of elevated collagen I and fibronectin in the ovarian cancer pre-metastatic niche. The goal is to improve understanding of the fundamental biological mechanisms underlying high-grade serous ovarian cancer (HGSOC), which has a 5-year survival rate of just 31%. The award, effective from December 11, 2024 to...
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $465,020 to the University of Maryland, Baltimore (UMB) to conduct research on the mechanisms by which chemotherapy can inadvertently promote metastasis in epithelial ovarian cancer. The research aims to determine how clinically approved chemotherapies activate tumor-associated membrane-anchored serine proteases (MASPs) in a way that potentiates tumor dissemination and metastatic...
- The National Cancer Institute awarded a $148,500 Project Grant under the Cancer Biology Research Program (CFDA 93.396) to the University of North Texas to evaluate the role of extracellular vesicles in modulating the tumor microenvironment, with a focus on their impact on T cell infiltration and suppression in non-small cell lung cancer (NSCLC) and prostate cancer. The project aims to identify specific subpopulations of tumor-derived extracellular vesicles, such as TGN46+ vesicles, that...
- The National Cancer Institute awarded a $936,746 Project Grant to Rutgers University for the research project "Cancer Cell-Intrinsic Mitochondrial Stress Responses Influence Protective Immunity" under the federal Cancer Biology Research grant program (CFDA 93.396). The goal of this 5-year project is to further understand how cancer cell mitochondrial dysfunction and stress responses affect immune responses in ovarian cancer, with a focus on a specific gene variant associated with...
- This federal Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) provides $192,240 to The University of Texas MD Anderson Cancer Center to conduct research on the functional contribution of extracellular vesicles in pancreatic cancer. The research aims to investigate how cancer cell-derived extracellular vesicles modulate the tumor microenvironment to facilitate pancreatic cancer initiation, progression, and metastasis. The goal is to identify novel...
- This Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) provides $101,340.00 to the Regents of the University of Michigan to conduct research focused on understanding the role of the MS4A14 protein in regulating macrophage activation and its impact on anti-tumor immunity. The award period runs from Dec 12, 2025 to Jun 16, 2028. The research aims to investigate how MS4A14 expression in macrophages influences their ability to present antigens and...
- This federal Project Grant award of $220,894 from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) aims to discover novel regulators of cellular deformability that can block the spread of chemoresistant ovarian cancer cells. The research will use a high-throughput cell filtration platform developed by the Rowat Laboratory at the University of California, Los Angeles (UCLA) to screen large libraries of small molecules and identify targets that can reverse the increased...
- This Project Grant award of $326,103 from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research by the University of Oklahoma Health Sciences Center to investigate the role of protein-nanoparticle interactions in understanding the multicellular crosstalk within the tumor microenvironment of ovarian and pancreatic cancers. The research aims to decipher the domains of the protein IGFBP2 that are responsible for driving this multicellular crosstalk, and to...
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research to develop a targeted therapy for acute myeloid leukemia (AML) with the chromosome inversion inv(16). The $545,170 award to Versiti Wisconsin, Inc. aims to characterize the mechanisms by which the oncogenic fusion protein CBFB-SMMHC activates the translation initiation factor EIF4G1, leading to AML transformation. The research will test whether inhibiting EIF4G1 can overcome...
- This federal Project Grant award of $677,787 from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research by the University of California, San Francisco (UCSF) to study the role of AIRE-expressing macrophages in tumor immune evasion. The research aims to define novel mechanisms by which tumors evade immune responses, with a focus on the function of these unique macrophage populations in the tumor microenvironment. The project will run from August 2025 through...